Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Dozens of doctors are routinely performing risky vascular ...

Current anti-angiogenic therapies using vascular endothelial growth factor-A/vascular endothelial growth factor receptor-2 (VEGF-A/VEGFR2) inhibitors lack dynamic biomarkers that can facilitate ...

A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial). This is an ...

Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC. Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs ...

RNA splicing, in which different coding RNA, or exons, are joined together after noncoding regions, or introns, are removed, allows for a large array of RNA transcript isoforms with distinct sequences ...

Showing a significant efficacy signal in a phase II trial, Relay Therapeutics Inc.’s zovegalisib (RLY-2608) achieved a 60% volumetric response in patients with PIK3CA-driven vascular anomalies (VAs).

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF ...

The U.S. economy expanded at an annual rate of 2% in the first three months of 2026, slower than forecasters expected but a rebound from weak growth in the previous quarter, new government data shows.

Fox has renewed Fear Factor: House of Fear, hosted by jackass Jackass star Johnny Knoxville, for a second season. “Fear Factor: House of Fear instantly established itself as a signature unscripted ...